ROCKVILLE, Md., Jan. 23, 2012 -MMG, a global clinical trial
patient recruitment group and part of Ketchum,
today announced
the addition of Chris Middleton as vice president of
technology.
Middleton oversees all new technology product and
application, service, and
infrastructure development. He
will provide leadership and strategic direction for MMG's
expanding portfolio of
technology-based patient recruitment
efforts.
"Welcoming a technology expert of Chris's caliber to our
accomplished leadership team underscores
MMG's commitment to better
enable individuals to connect with clinical trials through
technology," said John
Benbrook, CEO of MMG. "Chris's passion for
developing novel technology solutions that bridge gaps between
patients and the services they need is perfectly suited for
achieving MMG's aggressive goals for innovating and meeting
our clients' needs."
Middleton is a software industry veteran with an impressive
track record in complex software
development across the healthcare,
privacy, biometrics and enterprise integration industries,
both in the United States and internationally. In
addition to
serving as a software architect and technology manager
for companies such as CGI-AMS, Software AG, Deutsche Post DHL
and Daon, Chris has held leadership positions for software
startups and also founded Scaled Objects in 2007.
"I am thrilled to bring new patient recruitment technology
solutions to life with
MMG, a company with a strong commitment to
improving healthcare through the
acceleration of medical research,"
said Middleton. "It is a great time to
be a part of such a
skilled organization, and I am quickly working to further
its
innovation initiatives and achieve improved trial engagement
and recruitment results
on behalf of our clients."
Middleton is a graduate of Virginia Tech, a resident of
Alexandria, Va., and a passionate
technology futurist.
About MMG
MMG,
a Ketchum company and part of the Omnicom Group
(NYSE:OMC) family, is the premier global patient
recruitment and
retention organization. With experience in more than 70
countries
and across a vast range of therapeutic areas, populations, and
study
types, MMG provides strategies specially crafted for study
teams and patient
populations while delivering the best return on
investment for the sponsor.
# # #
